The role of pallidal serotonergic function in Parkinson's disease dyskinesias: A positron emission tomography study

Neurobiology of Aging

Volumn 36, Issue 4, 2015, Pages 1736-1742

  Smith, Ruben ^a,b   Wu, Kit ^b   Hart, Thomas ^b   Loane, Clare ^b   Brooks, David J ^b,c   Björklund, Anders ^d   Odin, Per ^a,e   Piccini, Paola ^b   Politis, Marios ^b,f  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c AARHUS UNIVERSITY   (Denmark)

^d LUND UNIVERSITY   (Sweden)

^e Central Hospital   (Germany)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dyskinesia; Globus pallidus; Parkinson's disease; Positron emission tomography; Serotonin

Indexed keywords

CARBIDOPA; DASB C 11; DOPAMINE 2 RECEPTOR; LEVODOPA; RADIOPHARMACEUTICAL AGENT; RADOPRIDE C 11; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; DOPAMINE; PROTEIN BINDING; SEROTONIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DOPAMINE BRAIN LEVEL; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; HUMAN; IMAGE ANALYSIS; MALE; PARKINSON DISEASE; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; SEROTONINERGIC NERVE CELL; THALAMOCORTICAL TRACT; TREATMENT RESPONSE; AGED; COMPLICATION; DYSKINESIAS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SYNAPSE;

AGED; DOPAMINE; DYSKINESIAS; FEMALE; GLOBUS PALLIDUS; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; SEROTONERGIC NEURONS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEVERITY OF ILLNESS INDEX; SYNAPSES;

EID: 84925237392     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.12.037     Document Type: Article

References (41)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16:448-458.
2. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989, 12:366-375.
3. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:2569-2574.
4. Carlsson T., Carta M., Winkler C., Björklund A., Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J.Neurosci. 2007, 27:8011-8022.
5. Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
6. Carta M., Carlsson T., Muñoz A., Kirik D., Björklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Mov. Disord. 2010, 25(Suppl 1):S174-S179.
7. de la Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., Ruth T.J., Stoessl A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
8. DeLong M., Wichmann T. Update on models of basal ganglia function and dysfunction. Parkinsonism Relat. Disord. 2009, 15(Suppl 3):S237-S240.
9. Di Matteo V., Pierucci M., Esposito E., Crescimanno G., Benigno A., Di Giovanni G. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders. Progress in Brain Research 2008, 423-463. Elsevier. G. Di Giovanni, V. DiMatteo, E. Esposito (Eds.).
10. Fahn S., Libsch L.R., Cutler R.W. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J.Neurol. Sci. 1971, 14:427-455.
11. Fischman A.J., Bonab A.A., Babich J.W., Palmer E.P., Alpert N.M., Elmaleh D.R., Callahan R.J., Barrow S.A., Graham W., Meltzer P.C., Hanson R.N., Madras B.K. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998, 29:128-141.
12. Forno L.S. Neuropathology of Parkinson's disease. J.Neuropathol. Exp. Neurol. 1996, 55:259-272.
13. German D.C., Manaye K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 1992, 32:667-676.
14. Ginovart N., Wilson A.A., Meyer J.H., Hussey D., Houle S. Positron emission tomography quantification of [(11)C]-DASB binding to the human serotonin transporter: modeling strategies. J.Cereb. Blood Flow Metab. 2001, 21:1342-1353.
15. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997, 6:279-287.
16. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., Larsen J.P., Lees A., Oertel W., Poewe W., Rascol O., Sampaio C. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur. J. Neurol. 2006, 13:1186-1202.
17. Hortnagl H., Schlögl E., Sperk G., Hornykiewicz O. The topographical distribution of the monoaminergic innervation in the basal ganglia of the human brain. Prog. Brain Res. 1983, 58:269-274.
18. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J.Neurol. Neurosurg. Psychiatry 1992, 55:181-184.
19. Jellinger K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 1991, 14:153-197.
20. Kish S.J., Furukawa Y., Chang L.J., Tong J., Ginovart N., Wilson A., Houle S., Meyer J.H. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?. Nucl. Med. Biol. 2005, 32:123-128.
21. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131:120-131.
22. Kita H., Chiken S., Tachibana Y., Nambu A. Serotonin modulates pallidal neuronal activity in the awake monkey. J.Neurosci. 2007, 27:75-83.
23. Kliem M.A., Pare J.F., Khan Z.U., Wichmann T., Smith Y. Ultrastructural localization and function of dopamine D1-like receptors in the substantia nigra pars reticulata and the internal segment of the globus pallidus of parkinsonian monkeys. Eur. J. Neurosci. 2010, 31:836-851.
24. Lees A.J., Shaw K.M., Stern G.M. "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease. Lancet 1977, 2:1034.
25. Lindgren H.S., Andersson D.R., Lagerkvist S., Nissbrandt H., Cenci M.A. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. J.Neurochem. 2010, 112:1465-1476.
26. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J.Cereb. Blood Flow Metab. 1996, 16:834-840.
27. Montgomery A.J., Thielemans K., Mehta M.A., Turkheimer F., Mustafovic S., Grasby P.M. Correction of head movement on PET studies: comparison of methods. J.Nucl. Med. 2006, 47:1936-1944.
28. Papa S.M., Desimone R., Fiorani M., Oldfield E.H. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann. Neurol. 1999, 46:732-738.
29. Parent A., Cossette M. Extrastriatal dopamine and Parkinson's disease. Adv. Neurol. 2001, 86:45-54.
30. Politis M., Oertel W.H., Wu K., Quinn N.P., Pogarell O., Brooks D.J., Bjorklund A., Lindvall O., Piccini P. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov. Disord. 2011, 26:1997-2003.
31. Politis M., Wu K., Loane C., Brooks D.J., Kiferle L., Bain P., Turkheimer F.E., Molloy S., Piccini P. The role of serotonergic mechanisms in Parkinson's disease dyskinesias. J.Clin. Invest. 2014, 124. in press.
32. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D.J., Piccini P. Staging of serotonergic dysfunction in Parkinson's disease: an invivo 11C-DASB PET study. Neurobiol. Dis. 2010, 40:216-221.
33. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., Bjorklund A., Lindvall O., Piccini P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci. Transl. Med. 2010, 2:38ra46.
34. Politis M., Wu K., Loane C., Turkheimer F.E., Molloy S., Brooks D.J., Piccini P. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010, 75:1920-1927.
35. Rommelfanger K.S., Wichmann T. Extrastriatal dopaminergic circuits of the basal ganglia. Front. Neuroanat. 2010, 4:139.
36. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., Descarries L., Cenci M.A. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68:619-628.
37. Smith J.M., Oswald W.T., Kucharski L.T., Waterman L.J. Tardive dyskinesia: age and sex differences in hospitalized schizophrenics. Psychopharmacology (Berl) 1978, 58:207-211.
38. Turkheimer F.E., Brett M., Visvikis D., Cunningham V.J. Multiresolution analysis of emission tomography images in the wavelet domain. J.Cereb. Blood Flow Metab. 1999, 19:1189-1208.
39. Wallman M.J., Gagnon D., Parent M. Serotonin innervation of human basal ganglia. Eur. J. Neurosci. 2011, 33:1519-1532.
40. Whone A.L., Moore R.Y., Piccini P.P., Brooks D.J. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann. Neurol. 2003, 53:206-213.
41. Zeng B.Y., Iravani M.M., Jackson M.J., Rose S., Parent A., Jenner P. Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia. Neurobiol. Dis. 2010, 40:599-607.